Earnings Insights · DexCom (DXCM) · Q3 FY2026

DexCom (DXCM) Q3 FY2026: Dexcom Q3 2026 Earnings: Margin Expansion and U.S. Growth Offset Slower International Sales

By AlgovestIQ ResearchPublished

Share

Read DexCom’s results announcement (Form 8-K, filed Oct 29, 2026)

Key earnings findings

DexCom (DXCM) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. DexCom reported Q3 FY2026 revenue of $1.34B against the $1.33B analyst estimate, a 1.2% beat, and EPS of $0.73 against the $0.68 analyst estimate, a 8.1% beat.
  2. Management said the revised revenue midpoint incorporates third-quarter outperformance, partly offset by roughly $5M of incremental foreign-exchange headwinds since the prior outlook.
  3. DXCM closed at $82.29 on Oct 30, 2026, up 3.0% from $79.93 on Oct 29, 2026, the last close before the results were released.

Sources: DexCom results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did DexCom beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$1.34B
$1.33B
+1.2%
EPS
$0.73
$0.68
+8.1%
  • EPS has beaten the estimate in 6 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from 0.4% to 2.9%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Dexcom reported third-quarter revenue of $1.344B, up 11% year over year, while GAAP diluted EPS increased to $0.72 from $0.70. Adjusted diluted EPS rose to $0.73 from $0.61 as gross margin and operating margin expanded sharply. The central investment takeaway was continued U.S. share gains and improved manufacturing execution, although international growth slowed to 5% as the company lapped prior reimbursement wins.

Management raised its 2026 revenue midpoint and increased its operating-margin and adjusted EBITDA-margin outlook. The next major growth variable remains a potential U.S. Medicare coverage expansion for people with Type 2 diabetes not using insulin, which Dexcom still expects to be decided this year and implemented around mid-2027.

Earnings Snapshot

MetricReportedChange
Revenue$1.344BUp 11% year over year
U.S. revenue$969.8MUp 14%
International revenue$374.7MUp 5%
Organic revenue growth11%—
GAAP gross profit$864.4MUp from $731.4M
GAAP gross margin64.3%Up 380 basis points
Non-GAAP gross margin65.1%Up 380 basis points
GAAP operating income$327.2MUp 35%
GAAP operating margin24.3%Up 420 basis points
Non-GAAP operating income$339.5MUp 24%
Non-GAAP operating margin25.3%Up 270 basis points
GAAP diluted EPS$0.72Up from $0.70
Non-GAAP diluted EPS$0.73Up from $0.61
Adjusted EBITDA$435.2MUp from $368.4M
Adjusted EBITDA margin32.4%Up 190 basis points
Cash, cash equivalents and marketable securities$1.82BRevolving credit facility undrawn

The Bigger Story

Dexcom’s quarter reinforced that its growth algorithm remains intact before any broad Medicare expansion for non-insulin Type 2 diabetes patients. Revenue grew 11% despite management’s prior assumption that no major coverage expansion would occur during 2026, and management said global new-patient starts were near record levels.

The quality of that growth was strongest in the U.S., where revenue accelerated to 14% growth from the first half and management said Dexcom gained share across customer segments. Management particularly highlighted gains among Type 2 patients, including people not using insulin. That matters because this population represents the company’s most significant potential access-driven growth opportunity, but coverage expansion has not yet occurred.

Margin improvement was equally important. Gross margin expanded 380 basis points year over year to 65.1% on a non-GAAP basis, reflecting manufacturing efficiencies, lower freight costs, improved quality management and the growing mix of the G7 15 Day sensor in the U.S. The company is now approaching the gross-margin level it has targeted longer term, though the startup of its Ireland manufacturing facility will create a near-term drag.

Revenue and Operating Performance

Worldwide revenue rose to $1.344B from $1.209B. Organic revenue was $1.346B, excluding a $1.7M foreign-exchange effect and $0.7M of acquired non-CGM revenue, also representing 11% growth.

U.S. revenue increased 14% to $969.8M. Distributor-channel sales accounted for $933.1M of U.S. revenue, up from $818.1M a year earlier, while direct U.S. sales rose to $36.7M from $33.8M. Management attributed the performance to share gains, strong new-patient starts and stable retention and utilization across a growing user base.

Management said active-user growth was in the upper teens, ahead of reported revenue growth. The difference suggests that patient growth remains solid but that revenue per active user, channel mix and timing continue to affect reported sales growth.

International revenue increased 5% to $374.7M. That represented a marked slowdown from Dexcom’s usual international growth profile, but management characterized it as a temporary comparison issue. The company is now lapping reimbursement wins achieved in the second half of 2025, which created a tougher year-over-year comparison in the third and fourth quarters of 2026.

Management expects international growth to return to higher organic levels at the start of 2027, supported by new access wins, the rollout of G7 15 Day and Dexcom ONE+ 15 Day, Stelo, Dexcom Flex and additional direct-market opportunities. That expectation will need to be validated, particularly because international markets can be affected by reimbursement timing, competitive pricing and distribution transitions.

G7 15 Day remains a key operating initiative. Management said adoption continued to build during the quarter and Dexcom remains on track to convert nearly 50% of its U.S. customer base to the longer-wear system by year-end. The company reported a four- to five-point improvement in 15 Day sensor survivability as the updated adhesive reached the market.

Dexcom also began commercial production at its Ireland facility on schedule. The plant expands capacity and diversifies production across the U.S., Europe and Asia-Pacific, but startup costs will weigh on near-term gross margin.

Profitability and Margins

GAAP gross profit rose to $864.4M, or 64.3% of revenue, from $731.4M, or 60.5% of revenue, a year earlier. Non-GAAP gross margin rose to 65.1% from 61.3%.

The margin expansion was notable because revenue grew 11% while cost of sales rose by less than 1%, to $480.1M from $477.9M. Manufacturing productivity, reduced freight expense, improved quality performance and G7 15 Day mix were the principal drivers cited by management.

GAAP operating income increased 35% to $327.2M, and GAAP operating margin increased to 24.3% from 20.1%. On a non-GAAP basis, operating income rose to $339.5M and operating margin reached 25.3%, up from 22.6%.

Operating expenses rose 10% on a GAAP basis to $537.2M. Research and development spending increased 3% to $161.6M, while selling, general and administrative expense rose 13% to $375.6M. Management said operating leverage would have been stronger absent investment in the Ireland facility.

GAAP net income declined slightly to $275.1M from $283.8M despite the operating improvement. The main reason was a decline in other income to $7.5M from $109.8M in the prior-year quarter. Non-GAAP net income rose to $275.0M from $242.5M, after excluding acquired-intangible amortization, business-transition items and tax adjustments.

Demand, Customers and Pricing

Management said the CGM category remains stable and that Dexcom’s U.S. share gains contributed meaningfully to growth. It cited continued physician awareness and adoption in Type 2 diabetes, including patients not using insulin, as important demand drivers.

The company said it has not seen meaningful pricing deterioration in either the U.S. or international markets. Management acknowledged that market conditions differ by geography, particularly in markets where an incumbent supplier may face new competition, but said Dexcom’s own pricing and reimbursement levels have remained stable.

A formulary change involving a CVS-related pharmacy-benefit arrangement is a potential issue for 2027. Management said the affected arrangement represents less than 4% of U.S. revenue and expects the financial impact to be limited because some patients may remain on Dexcom through non-preferred pharmacy access, prior authorization, cash pay or medical-benefit and durable-medical-equipment channels.

Dexcom plans to launch Dexcom Direct early next year to help patients navigate those coverage options. The program was initially intended to support broader Medicare access, but it could also reduce disruption for patients affected by formulary changes. Management said 2027 formularies are already substantially set and maintained that most U.S. access remains co-preferred with competitors.

What Is Dexcom’s Guidance for Full-Year 2026?

Dexcom raised the midpoint of its revenue outlook and now expects:

  • Revenue of $5.20B to $5.25B, representing approximately 12% to 13% growth
  • Non-GAAP gross margin of approximately 64%
  • Non-GAAP operating margin of approximately 24%
  • Adjusted EBITDA margin of approximately 32%

Management said the revised revenue midpoint incorporates third-quarter outperformance, partly offset by roughly $5M of incremental foreign-exchange headwinds since the prior outlook. The guidance implies approximately 10% revenue growth at the midpoint in the fourth quarter.

Management expects the Ireland facility startup to pressure gross margin in the fourth quarter and into early 2027. However, it also expects the growing proportion of G7 15 Day sales, manufacturing efficiencies and the absence of Ireland startup investment after the ramp period to support further margin progression.

The company continues to expect a Medicare coverage decision this year for non-insulin Type 2 diabetes patients, with implementation around the middle of 2027. That timing remains a management expectation, not a completed regulatory or reimbursement action.

Balance Sheet, Cash Flow and Capital

Dexcom ended September with $1.82B in cash, cash equivalents and marketable securities, while its revolving credit facility remained undrawn. The company also had $1.24B of long-term senior convertible notes.

Management said Dexcom generated more than $900M of free cash flow through the first nine months of 2026. It used that financial capacity to complete its previously stated goal of repurchasing $1B of stock during 2026.

The board authorized an additional $1B repurchase program alongside third-quarter results. Management said this is consistent with its commitment to deploy at least 50% of free cash flow generated through 2027 toward repurchases.

Dexcom also signed an agreement to acquire an international distribution business serving high-potential European markets. The transaction has not yet closed and will not affect 2026 results. Management described it as its largest remaining European distributor market and expects moving direct to create a future growth lever, though it will require investment to build direct operations.

What Investors Should Watch

1. Medicare Coverage for Non-Insulin Type 2 Diabetes

A favorable coverage decision and mid-2027 implementation would materially expand Dexcom’s addressable reimbursed population. The timing, scope and commercial-payer follow-through will determine how quickly that opportunity converts into revenue.

2. International Growth Reacceleration

International revenue grew only 5% in the third quarter. Management expects growth to improve in early 2027 as reimbursement comparisons normalize and new products launch, but investors should look for evidence that those drivers offset competitive and pricing pressures.

3. G7 15 Day Adoption and Gross Margin

The conversion of nearly half the U.S. installed base by year-end is a meaningful product-cycle milestone. A continued shift toward 15 Day sensors, along with improved sensor survivability, could support manufacturing efficiency and margin expansion.

4. Ireland Manufacturing Ramp

Ireland increases capacity and supply-chain resilience but creates short-term cost absorption pressure. The pace at which the facility reaches efficient production levels will affect 2027 gross-margin progression.

5. Formulary Retention and Dexcom Direct Execution

Management expects the CVS-related formulary change to have limited financial impact, but patient retention through pharmacy, prior authorization and medical-benefit channels remains an execution test. Dexcom Direct will be an important tool in limiting friction as access becomes more complex.

AlgovestIQ Takeaway

Dexcom’s third quarter was stronger than the headline 11% revenue growth alone suggests. U.S. sales accelerated to 14%, new-patient starts approached record levels, and the company expanded gross margin by 380 basis points while continuing to invest in capacity and product development.

The financial improvement was especially visible below the revenue line. Non-GAAP operating margin reached 25.3%, above the company’s approximately 24% full-year target, and adjusted EBITDA margin reached 32.4%. The company’s ability to improve profitability while funding Ireland, G7 15 Day commercialization, clinical studies and direct-access capabilities supports management’s view that operating leverage can continue over time.

The unresolved issue is the pace and durability of growth outside the U.S. International revenue slowed to 5%, and the company’s explanation rests on reimbursement comparisons rather than a structural demand change. That may prove correct, but international growth needs to reaccelerate in 2027 for Dexcom to sustain its broader growth profile without relying disproportionately on U.S. performance.

The larger upside case remains tied to reimbursement expansion for non-insulin Type 2 diabetes. Dexcom’s CONNECT study adds important clinical support, and management believes it will help shape standards of care and Medicare coverage decisions. Still, investors should treat that opportunity as contingent on coverage decisions, implementation timing and physician adoption rather than as near-term revenue already secured.

For now, Dexcom has strengthened its operating position: share gains, improving product performance, higher margins and substantial cash generation provide a solid base. The key question entering 2027 is whether that base can translate into another phase of growth as international comparisons ease, G7 15 Day becomes the majority product and broader reimbursement access potentially opens.

How did DXCM stock react?

DXCM closed at $82.29 on Oct 30, 2026, up 3.0% from $79.93 on Oct 29, 2026, the last close before the results were released.

SessionCloseChange
Oct 29, 2026 (before release)$79.93—
Oct 30, 2026$82.29+3.0%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: DexCom Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: DexCom Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against DexCom's earnings release and call transcript before publication. Not investment advice.